Overview

Capadenoson in Angina Pectoris

Status:
Withdrawn

Trial end date:
2008-11-01

Target enrollment:

Participant gender:

Summary

This is a multi-center and multi-national,randomized, double blind, placebo-controlled, 28-day treatment study with BAY 68-4986 taken orally or a matching placebo.

Phase:

Phase 2

Details

Lead Sponsor:

Bayer